• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

    2/13/24 4:05:17 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    SC 13G/A 1 fp0086862-22_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 5)*

     

    FONAR CORP

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    344437405

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

    [  ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 344437405   13G   Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Kayne Anderson Rudnick Investment Management, LLC

    95-4575414

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [ ]

    (b) [ ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    A California Limited Liability Company

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    632,569 

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    632,569

    8.

    SHARED DISPOSITIVE POWER

     

    0 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    632,569 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.81%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     


     

     

    CUSIP No. 344437405   13G   Page 3 of 5 Pages

     

    Item 1. (a)

    Name of Issuer

    Fonar Corp

         
      (b)

    Address of Issuer’s Principal Executive Offices

    110 Marcus Drive, Melville, NY 11747

     

    Item 2. (a)

    Name of Person Filing

    Kayne Anderson Rudnick Investment Management, LLC 

         
      (b)

    Address of the Principal Office or, if none, residence

    2000 Avenue of the Stars, Suite 1110, Los Angeles, CA 90067 

         
      (c)

    Citizenship

    A California Limited Liability Company 

         
      (d)

    Title of Class of Securities

    Common Stock

         
      (e)

    CUSIP Number

    344437405

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 344437405   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 632,569
    (b) Percent of class: 9.81%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 632,569
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose or to direct the disposition of: 632,569
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ] .

    Instruction. Dissolution of a group requires a response to this item.

     

    N/A

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A 

     

     

    CUSIP No. 344437405   13G   Page 5 of 5 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Kayne Anderson Rudnick Investment Management, LLC
         
      By:  /s/ Michael Shoemaker
      Name:  Michael Shoemaker
      Title:  Chief Compliance Officer
      Date:  February 13, 2024

     

     

    Get the next $FONR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:41:44 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:16:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    SEC Filings

    See more
    • Fonar Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - FONAR CORP (0000355019) (Filer)

      5/19/25 3:07:18 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Fonar Corporation

      10-Q - FONAR CORP (0000355019) (Filer)

      5/15/25 2:14:54 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Fonar Corporation

      DEF 14A - FONAR CORP (0000355019) (Filer)

      4/7/25 3:03:53 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period

      Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income Per Common Share Available to Common Stockholders increased 37% to $0.37 per share for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024.Total Revenues-Net increased 6% to $27.2 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Total Cash, Cash Equivalents and Short-Term Investments decreased 4% to $54.4 million at March 31, 2025 as compar

      5/15/25 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

      MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024. Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0

      2/18/25 7:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Leadership Updates

    Live Leadership Updates

    See more
    • FONAR Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

      3/20/23 11:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

      11/23/21 2:07:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Financials

    Live finance-specific insights

    See more
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

      Total MRI scan volume at the HMCA-managed sites increased 7% to 49,451 scans for the quarter ended March 31, 2023 versus the corresponding quarter one year earlier. For the nine-month period ended March 31, 2023, 139,339 scans were performed as compared to 140,650 for the corresponding nine-month period one year ago.Net Income increased 37% to $4.5 million for the quarter ended March 31, 2023 and decreased 27% to $9.9 million for the nine-month period ended March 31, 2023. Diluted Net Income Per Common Share Available to Common Stockholders increased 72% to $0.55 for the third fiscal quarter ended March 31, 2023 and decreased 19% to $1.16 for the nine-month period ended March 31, 2023. Tota

      5/15/23 4:05:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%

      Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year. Book Value Per Share increased by 6% to $20.41 per s

      9/28/21 7:30:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      11/14/24 12:27:58 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      2/13/24 5:04:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

      SC 13G/A - FONAR CORP (0000355019) (Subject)

      2/13/24 4:05:17 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care